Community Acquired Viral Pneumonia

Slide 1 · Community-Acquired

Viral Pneumonia

Pathology, mechanisms and clinicopathologic interpretation

Influenza • human metapneumovirus • shared viral lung injury

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Identify the principal viruses and host factors linked to pulmonary spread.

Explain influenza entry, antigenic variation and host injury mechanisms.

Recognize interstitial lung injury and complications of viral pneumonia.

Distinguish viral injury from superimposed bacterial pneumonia.

Apply the mechanisms to influenza and human metapneumovirus cases.

Slide 3 · Community-acquired pneumonia: Clinical setting

Infection develops outside the hospital environment.

The community-acquired syndrome includes both bacterial and viral causes.

Clinical and radiologic appearances often cannot securely distinguish the etiologies.

Identifying the pathogen and severity remains clinically important.

Slide 4 · Viral respiratory infection spans two compartments

Upper tract

Many infections manifest as a relatively mild common cold.

Lower tract

Extension to bronchioles or lung parenchyma can cause more severe disease.

Consequences

Epithelial injury, inflammation and impaired host defense.

The same virus can produce different clinical severity in different hosts.

Slide 5 · Viruses included in the Robbins differential

Examples

Clinical emphasis

Influenza A and B

Frequent community respiratory viruses; Influenza can be epidemic.

RSV / human metapneumovirus

Important especially in pediatric disease.

Adenovirus / rhinovirus

Can affect upper or lower respiratory tract.

Rubeola / varicella

Also included among potential viral pulmonary pathogens.

Examples are nonexclusive; Species-specific features are not asserted here.

Slide 6 · Age associations vary by agent

Children

RSV, parainfluenza and human metapneumovirus are listed among community-acquired viral causes in children.

Adults

Influenza A and B are highlighted among community-acquired viral causes in adults.

These are teaching associations, not exclusive age boundaries.

Slide 7 · When does a respiratory virus reach the lung?

Extremes of age favor lower respiratory extension.

Malnutrition or alcoholism can weaken resilience.

Underlying debilitating illness predisposes to more severe infection.

Host vulnerability modifies the same pathogen’s outcome.

Slide 8 · Shared mechanism of viral pneumonia

Attachment

Virus binds a susceptible respiratory epithelial cell.

Entry and replication

Viral gene expression produces cytopathic effects.

Injury

Death of infected cells and secondary inflammation.

Failure of defenses

Impaired mucociliary clearance permits further infection.

The sequence is general; Specific molecular receptors and proteins differ among viruses.

Slide 9 · Respiratory epithelium as the initial target

AIRWAY / ALVEOLAR LUMEN

SUBEPITHELIAL TISSUE / SEPTAL COMPARTMENT

SCHEMATIC

Interpretation

Viruses require entry into epithelial host cells.

Infected epithelium sustains direct damage.

Mucosal defense depends on intact epithelial function.

Slide 10 · Cytopathic injury and inflammatory amplification

Viral replication

Host-cell gene expression is disrupted.

Epithelial death

Damaged cells lose barrier functions.

Host response

Resident and recruited leukocytes contribute inflammation.

Direct viral cytotoxicity and secondary host inflammation together shape the lung lesion.

Slide 11 · Why the mucociliary barrier matters

AIRWAY / ALVEOLAR LUMEN

SUBEPITHELIAL TISSUE / SEPTAL COMPARTMENT

Cell injury / inflammation

SCHEMATIC

Interpretation

Epithelial damage impairs mucociliary clearance.

Retained secretions favor secondary bacterial invasion.

Superimposed pneumonia may be more serious than the viral injury.

Slide 12 · Two outcomes of viral epithelial damage

Viral inflammation

Interstitial mononuclear inflammation and epithelial cytopathy predominate.

Bacterial superinfection

Suppurative airway and alveolar inflammation can be superimposed, often with neutrophil-rich exudate.

Histologic patterns can overlap, especially in severe or mixed infection.

Slide 13 · Influenza: Main teaching model

Influenza A is a major cause of epidemics and pandemics.

Influenza A infects humans as well as several animal hosts.

Hemagglutinin and neuraminidase are key surface virulence proteins.

The segmented viral genome permits major antigenic changes.

Slide 14 · Influenza virus: Functional surface organization

Hemagglutinin (HA)

Attachment and endosomal membrane fusion.

Neuraminidase (NA)

Cleavage of sialic acid aids virion release.

Lipid envelope / RNA genome

Viral proteins reside in envelope; RNA is segmented.

Schematic • not to molecular scale

Slide 15 · HA and NA: What they do

Hemagglutinin recognizes sialic acid residues on target-cell surfaces.

Acidification after uptake promotes HA-mediated fusion.

Neuraminidase cleaves sialic acid to release budding progeny virions.

Antibodies directed against HA and NA confer distinct protective effects.

Slide 16 · Influenza attachment and penetration

Binding

HA attaches to surface sialic acid residues.

Endocytosis

Virus enters an endosomal vesicle.

Acidification

Low pH changes HA conformation.

Fusion

Viral envelope fuses; Genomic RNAs are released.

The HA protein participates in attachment and acid-triggered entry.

Slide 17 · Neuraminidase completes the infectious cycle

Progeny assembly

New virus particles form in infected epithelium.

Budding

Virions remain associated with sialic acid-containing surfaces.

NA cleavage

Sialic acid removal facilitates virion release.

HA facilitates entry; NA facilitates departure.

Slide 18 · Influenza genome and antigen identity

Eight single-stranded RNA segments comprise the influenza genome.

Nucleoproteins packaging these RNAs contribute to type assignment.

Influenza types A, B and C.

Segmented organization is central to understanding antigenic shift.

Slide 19 · Influenza A subtype notation: HA and NA

H = hemagglutinin

Examples emphasized in this Robbins discussion: H1, H2 and H3.

N = neuraminidase

Examples emphasized in this Robbins discussion: N1 and N2.

Example format: H1N1

The listed subtypes are textbook examples, not a complete HA/NA subtype inventory.

Slide 20 · Antigenic drift versus antigenic shift

Antigenic drift

Spontaneous mutations change epitopes of HA and/or NA.

Prior antibodies may still confer partial protection.

Antigenic shift

Major replacement of viral HA and NA genetic material via animal-origin influenza viruses.

Population susceptibility can increase markedly.

Drift → epidemics; Shift → pandemic potential in the source account.

Slide 21 · How antigenic drift permits repeat epidemics

Existing immunity

Antibodies recognize earlier viral HA/NA epitopes.

Mutations

Viral surface epitopes change.

Immune escape

Prior recognition becomes incomplete.

New epidemic strain

Some previously immune hosts become susceptible.

Partial prior immunity can remain when epitopes are similar.

Slide 22 · Antigenic shift: A population-level change

Human and animal strains

Animal-origin gene segments enter influenza A lineage.

Major HA/NA change

Distinct surface antigen configuration emerges.

Limited prior protection

Population lacks broad pre-existing antibodies.

Shift is the major-change mechanism associated with pandemics in the text.

Slide 23 · Why drift and shift differ clinically

Drift → epidemic pattern

Smaller antigenic changes yield novel circulating strains with some retained immunity.

Shift → pandemic potential

Major surface-protein replacement may expose a large population to unfamiliar viral antigens.

Pandemic emergence also depends on transmission; Antigenic change alone is not sufficient.

Slide 24 · Influenza pandemics: Historical observations

The 1918 pandemic is discussed using viral genetic material recovered from historical lung tissue.

Sequences consistent with a swine-influenza origin.

The 2009 pandemic also involved a virus of swine origin.

Historical molecular analysis links pathogen evolution with population susceptibility.

Slide 25 · The 2009 pandemic and population immunity

Younger adults

Severe infections were conspicuous in young adults during the 2009 pandemic, according to the textbook.

Older adults

Antibodies against some previous strains appeared to confer partial protection.

Historical example; Not a prediction about contemporary circulating variants.

Slide 26 · Influenza severity modifiers

Diabetes, heart disease and lung disease increase vulnerability.

Immunosuppression predisposes to severe infection.

Immune history and previous exposure can alter susceptibility.

Risk reflects interaction between viral antigenicity and host condition.

Slide 27 · Avian influenza: The textbook risk concept

Avian strains circulate principally among birds.

The source specifically discusses H5N1 as a potential pandemic concern.

The scenario requires a virus both antigenically novel and capable of sustained human-to-human spread.

This is a conceptual risk model, not a current surveillance assessment.

Slide 28 · Influenza pneumocyte injury sequence

Entry

Influenza infects susceptible pneumocytes.

Early transport dysfunction

Inhibition of sodium channels favors alveolar fluid shifts.

Cell death

Translation interference and caspase activation injure epithelium.

Inflammation

Danger signals and cytokines recruit host responses.

Multiple epithelial and inflammatory mechanisms generate lung dysfunction.

Slide 29 · Fluid in the alveolus: An early mechanism

Infected pneumocyte

Influenza-associated interference with sodium transport.

Fluid homeostasis changes

Electrolyte and water movement becomes abnormal.

Alveolar fluid

Luminal fluid accumulation impairs aeration.

This is a mechanistic model described for influenza, not a universal viral channel mechanism.

Slide 30 · Influenza triggers epithelial cell death

Virus replication

Host-cell mRNA translation becomes inhibited.

Caspases

Apoptotic machinery is activated.

Epithelial loss

Loss of epithelial integrity increases alveolar injury.

Influenza epithelial cytotoxicity includes direct cell damage and programmed cell death.

Slide 31 · Epithelial death amplifies edema

Loss of epithelial cells compounds pre-existing fluid accumulation.

Dying cells release signals that activate tissue-resident macrophages.

The resulting inflammation spreads beyond directly infected epithelial cells.

The final lung injury reflects both virus and host response.

Slide 32 · Danger signals recruit macrophage responses

Damaged epithelial cells

Release injury-associated signals.

Resident macrophages

Sense the signals and become activated.

Inflammatory mediators

Amplify local tissue response.

Macrophages participate in amplification even when not the original infected cell.

Slide 33 · Cytokines and chemokines propagate inflammation

Infected epithelium

Releases inflammatory chemokines and cytokines.

Macrophages

Release additional inflammatory mediators.

Pulmonary endothelium

Responds to activation signals.

Neutrophil migration

Cells enter the interstitium early in illness.

Inflammation can extend to neighboring pulmonary tissue.

Slide 34 · Neutrophils in an influenza-injured lung

Mediators activate pulmonary endothelium and chemoattract neutrophils.

Neutrophils migrate into the interstitium within the initial days.

Severe viral injury can therefore contain neutrophils in addition to mononuclear cells.

Cellular composition must be interpreted in the clinical and microbiologic context.

Slide 35 · Influenza: Two pathways to severe pneumonia

Direct severe viral lung injury

Extensive epithelial damage and inflammation can culminate in acute respiratory distress syndrome (ARDS).

Secondary bacterial pneumonia

Viral impairment of local defenses permits bacterial infection; This is often the more serious complication.

These mechanisms may coexist.

Slide 36 · Why bacterial pneumonia can follow influenza

Viral infection

Injures respiratory epithelium and mucociliary barrier.

Defense impairment

Reduced clearance supports bacterial invasion.

Superinfection

Bacteria produce additional destructive/suppurative inflammation.

Look for new or worsening symptoms following an apparent viral illness.

Slide 37 · Staphylococcus aureus following influenza

S. Aureus as a particularly important secondary cause.

Postviral staphylococcal pneumonia can be life-threatening.

Staphylococcal lung infections may also produce abscesses and empyema.

A severe course after influenza should prompt consideration of superinfection.

Slide 38 · Innate interferon response to influenza

Viral products in infected cells

Triggers host defense

Type I interferon

Induces antiviral gene expression

MX1 GTPase

Interferes with viral transcription and replication

Different immune mechanisms cooperate; Neither arrow represents a quantitative effect.

Slide 39 · MX1: A specific antiviral host mechanism

Viral products stimulate type I interferon responses.

Type I interferons increase MX1 gene expression.

MX1 encodes a guanosine triphosphatase.

The encoded product interferes with influenza transcription and replication.

Slide 40 · Cell-mediated control of infected pneumocytes

Viral antigens and infected cells

Triggers host defense

NK cells / cytotoxic T cells

Recognize and kill infected cells

Reduced infected-cell reservoir

Limits spread to nearby pneumocytes

Different immune mechanisms cooperate; Neither arrow represents a quantitative effect.

Slide 41 · Adaptive antibodies complete influenza control

Infection and antigen

Viral HA and NA generate humoral responses.

Anti-HA antibodies

Can block infection through neutralization.

Anti-NA antibodies

Can ameliorate infection by interfering with release.

Cellular and antibody-mediated arms are complementary.

Slide 42 · Host protection occurs at several steps

Mechanism

Primary effect

Type I IFN / MX1

Intracellular antiviral program interferes with replication.

NK cells and cytotoxic T cells

Kill infected cells and constrain spread.

Anti-HA antibodies

Prevent or neutralize viral entry.

Anti-NA antibodies

Reduce efficient release and spread of virions.

Slide 43 · Human metapneumovirus: Overview

A respiratory paramyxovirus identified in 2001 account.

Circulates worldwide and affects both upper and lower airways.

Illness may range from mild infection to severe bronchiolitis or pneumonia.

Presents across the age spectrum, with clear vulnerable groups.

Slide 44 · Human metapneumovirus: Vulnerable hosts

Young children

First infection often occurs in early childhood; Bronchiolitis and pneumonia may be severe.

Older or immunocompromised

Reinfection is common over life; Severe illness is especially important in elderly and immunocompromised individuals.

Slide 45 · Human metapneumovirus in pediatric disease

A substantial role in pediatric acute respiratory illness.

Reported estimates are 5–10% of hospitalizations of children with acute respiratory infection.

Reported estimates are 12–20% of outpatient visits in the same context.

These are source-era estimates, not a universal rate or 2026 surveillance statistic.

Slide 46 · Clinical overlap: HMPV versus RSV

Human metapneumovirus

Upper and lower respiratory disease, including bronchiolitis and pneumonia.

Respiratory syncytial virus

A clinically similar illness; The two are often indistinguishable on symptoms alone.

The textbook also notes that hMPV illness is sometimes mistaken for influenza.

Slide 47 · Repeated hMPV infections across the life span

Early childhood

First infection generally occurs early.

Subsequent exposures

Reinfections remain common.

Vulnerable older age

Reinfection can be clinically important in older hosts.

Past infection does not imply lifelong sterilizing protection.

Slide 48 · Human metapneumovirus: Diagnostic rationale

Overlapping syndrome

Symptoms resemble RSV or influenza.

Etiologic uncertainty

Clinical diagnosis alone may misclassify the virus.

PCR testing

Viral RNA amplification supports pathogen identification.

PCR is an etiologic tool; The source does not provide performance characteristics.

Slide 49 · Human metapneumovirus: Management context

The Robbins discussion emphasizes supportive care.

Severe disease must be recognized in susceptible hosts.

At publication, the absence of a clinically effective, safe vaccine.

Do not use a source-era statement as proof of current therapeutic or vaccine status.

Slide 50 · Shared viral pneumonia: Gross distribution

Lung involvement can be patchy or involve entire lobes.

Involvement may be unilateral or bilateral.

Affected areas are described as red-blue and congested.

Pleuritis and pleural effusions are generally infrequent.

Slide 51 · Interstitial inflammation is the dominant pattern

Alveolar parenchyma — simplified schematic

Thickened septa + mononuclear cells

What the pattern means

Alveolar septa become thickened and edematous.

Lymphocytes, macrophages and occasional plasma cells infiltrate septa.

The lesion is centered on alveolar walls, not solely alveolar spaces.

SCHEMATIC — not H&E

Slide 52 · Normal airspace versus inflamed septum

Alveolar parenchyma — simplified schematic

Relatively thin septal boundaries

What the pattern means

Compare with the preceding interstitial pattern.

A thinner interstitium permits a short gas diffusion pathway.

Septal expansion and inflammation increase the barrier to gas exchange.

SCHEMATIC — not H&E

Slide 53 · Histologic constituents of viral interstitial disease

Alveolar septal edema is a consistent structural response.

Mononuclear cells predominate: Lymphocytes and macrophages.

Plasma cells can be present; Neutrophils appear in severe cases.

Alveolar spaces may be clear or contain proteinaceous and cellular exudate.

Slide 54 · Alveolar proteinaceous exudate in severe disease

Alveolar parenchyma — simplified schematic

Protein / cell exudate in airspaces

What the pattern means

Fluid and protein may accumulate in alveolar lumina.

Cellular exudation occurs in many affected lungs.

The pattern becomes more complex as disease severity increases.

SCHEMATIC — not H&E

Slide 55 · Acute respiratory distress syndrome pattern

Alveolar parenchyma — simplified schematic

Hyaline membrane segments (red lines)

What the pattern means

Diffuse acute lung injury may complicate severe viral pneumonia.

Hyaline membranes may line alveolar walls.

The membranes reflect a severe injury response, not a virus-specific diagnostic marker.

SCHEMATIC — not H&E

Slide 56 · From small-airway injury to atelectasis

Mucosal swelling

Bronchiolar lumen becomes narrower.

Secretions and debris

Mucus, fibrin and inflammatory exudate may obstruct airways.

Air trapping or collapse

Complete plugging may produce focal atelectasis.

The source specifically links small-airway plugging with focal atelectasis.

Slide 57 · Prolonged bronchiolar injury can scar

Severe bronchiolitis

Persistent debris and inflammatory obstruction.

Organization

Luminal exudate may organize and fibrose.

Obliterative bronchiolitis

Permanent small-airway damage may remain.

Uncommon severe outcome, not the usual course of viral respiratory infection.

Slide 58 · Upper airway morphology in viral infection

Mucosal hyperemia and edema narrow the upper passages.

Mononuclear cells enter the submucosa.

Excess mucus can obstruct nasal, sinus and Eustachian passages.

This favors secondary bacterial complications; Tonsillar lymphoid hyperplasia is frequent in children.

Slide 59 · Airway epithelium and bacterial superinfection

AIRWAY / ALVEOLAR LUMEN

SUBEPITHELIAL TISSUE / SEPTAL COMPARTMENT

Cell injury / inflammation

SCHEMATIC

Interpretation

Disrupted mucociliary function impairs defense.

Secondary bacterial inflammation increases suppuration.

Infection may extend from bronchi and bronchioles into lung parenchyma.

Slide 60 · Morphology of viral and bacterial pneumonia

Predominantly viral

Septal widening and edema.

Interstitial mononuclear inflammation.

Variable intraalveolar protein and cells.

Secondary bacterial component

Ulcerative bronchitis or bronchiolitis.

Suppurative alveolar inflammation.

Neutrophil-rich consolidation may dominate.

Morphologic clues require clinical and microbiologic correlation.

Slide 61 · Necrotizing viral airway injury: Exceptions

Certain viruses can cause prominent epithelial necrosis.

Herpes simplex virus, varicella and adenovirus.

Necrosis can affect bronchial and alveolar epithelium.

Viral cytopathic effects may assist interpretation, but are not uniform across viruses.

Slide 62 · Symptoms may underestimate viral pneumonia

Patients may describe a chest cold rather than pneumonia.

Cough can be absent or relatively unremarkable.

Fever, headache and myalgia may dominate the clinical syndrome.

Physical findings may be limited even when substantial lung injury exists.

Slide 63 · Why hypoxemia can seem out of proportion

Interstitial edema and exudate

Alveolar function becomes heterogeneous.

V/Q mismatch

Ventilation no longer matches local perfusion.

Arterial hypoxemia

Gas exchange fails despite scant auscultatory signs.

V/Q = ventilation–perfusion.

Slide 64 · Variable course and resolution

Many viral pneumonias are mild and self-limited.

The usual course is resolution without lasting structural sequelae.

Eradication of infection can be followed by restoration of lung architecture.

Severe cases may instead develop ARDS, secondary infection or airway scarring.

Slide 65 · Why epidemics carry large clinical consequences

Individual patient

Even when a viral infection is usually mild, susceptible hosts may develop severe complications.

Population burden

Widespread transmission produces substantial total morbidity, even if a minority of infections become severe.

Slide 66 · Case exercise: Limited chest findings, severe hypoxemia

Presentation

A patient has fever, myalgia and relatively little cough. Respiratory examination is not striking, but oxygenation is impaired.

Pathologic reasoning

Septal edema and intraalveolar exudate can create ventilation–perfusion mismatch without prominent localizing signs.

Teaching vignette synthesized from described textbook features; No actual patient data.

Slide 67 · Case exercise: Deterioration after influenza

Clinical change

Following an influenza-like illness, respiratory symptoms worsen with features suggesting a new bacterial process.

Most important mechanism

Damaged epithelium and impaired clearance permit superinfection; Consider severe S. Aureus pneumonia.

A diagnostic reasoning vignette, not a claim about a specific patient.

Slide 68 · A practical etiologic reasoning framework

Observation

Interpretive significance

Upper tract onset → pulmonary illness

May represent downward extension of viral respiratory infection.

Minimal focal signs despite hypoxemia

Consistent with interstitial edema and ventilation–perfusion mismatch.

Clinical worsening after influenza

Consider secondary bacterial pneumonia, including S. Aureus.

HMPV-like syndrome

PCR can identify hMPV when symptoms overlap other viruses.

Slide 69 · Integrated pathway: Virus to physiologic disease

Viral attachment / entry

Respiratory epithelium becomes infected.

Cell injury / inflammatory response

Septal edema, interstitial cells and alveolar fluid.

Impaired gas exchange

Ventilation–perfusion mismatch and hypoxemia.

Recovery or complication

Restoration, ARDS or bacterial superinfection.

Disease severity reflects the balance between tissue injury and effective host defense.

Slide 70 · Final synthesis: What pathology explains

Respiratory epithelial tropism initiates the infection.

Virus-induced cell damage recruits inflammatory responses.

Interstitial and alveolar injury explain hypoxemia despite limited signs.

Influenza adds HA/NA biology, antigenic drift and shift, and specific host responses.

Loss of mucociliary defenses links viral disease to dangerous bacterial pneumonia.

Slide 71 · References and source boundary

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026). Chapter 15, “The Lung.”

Core topic: Community-Acquired Viral Pneumonia; influenza and human metapneumovirus, pp. 646–648.

General viral respiratory morphology and clinical features, adjacent discussion, pp. 648–649.

Clinical setting and bacterial pneumonia comparator: pulmonary infections, pp. 643–646.

Textbook-based lecture. No independent update of current vaccines, guidelines or surveillance.